| Budget Amount *help |
¥19,630,000 (Direct Cost: ¥15,100,000、Indirect Cost: ¥4,530,000)
Fiscal Year 2016: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2015: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2014: ¥8,450,000 (Direct Cost: ¥6,500,000、Indirect Cost: ¥1,950,000)
Fiscal Year 2013: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
|
|---|
| Outline of Final Research Achievements |
Accumulating evidences have been indicating the involvement of epigenetic dysregulation in various type of diseases, and it accelerates the drug development targeting epigenetic modifiers. Among such modifiers, DOT1L, a histone methyltransferase, has been demonstrated as a promising target for several types of leukemia. In this study, we utilized a peptide library screening system called “RaPID system”, and identified a peptide which inhibits the catalytic activity of DOT1L comparable to an existing commercially-available inhibitor. Thus, our finding not only proposes another inhibitor of DOT1L for leukemia therapy but also suggests peptide libraries for an useful source of epidrugs.
|
